FDA’s Center for Drug Evaluation and Research’s (CDER) Office of New Drugs (OND) recently launched a pilot program on Novel Excipient Review. The pilot program offers a new pathway for drug manufacturers to obtain FDA review of certain novel excipients (inactive ingredients)
Similar Posts
In Response to a Broader FDA Investigation, ByHeart Initiates a Voluntary Recall of Two Batches of Infant Formula
[New York, NY] – ByHeart, a next-generation baby nutrition company, announced today that, out of an abundance of caution, it has chosen to voluntarily recall two batches of ByHeart Whole Nutrition Infant Formula following notification from the U.S. Food and Drug Administration (FDA) of a broader ongFrom Our Perspective
Insights from CDER leadership and experts on public health actionsAvoiding Products Contaminated with Hidden Ingredients
Many products claiming to help with health issues hide dangerous drug ingredients. Get informed about how to avoid contaminated products and their hidden ingredients.Regulatory Education for Industry (REdI) Annual Conference 2024: Innovation in Medical Product Development – 05/29/2024
Regulatory Education for Industry (REdI) Annual Conference 2024: Innovation in Medical Product DevelopmentAurobindo Pharma USA Inc – 05/15/2024
Aurobindo Pharma USA Inc – 05/15/2024. Country: United States. Record Type: 483CDER Data Standards Program
CDER Data Standards Program